Gilead moves to bolster cancer pipeline with €3 billion german biotech buyout

Gilead Sciences has officially struck a deal to buy Munich-based Tubulis GmbH, a clinical-stage biotech specialising in a next-generation class of cancer treatments known as antibody-drug conjugates. The move significantly deepens Gilead’s oncology ambitions, with CEO Daniel O’Day describing it as adding to what he called the strongest and most diverse pipeline in the company’s history.

Note that the ADCs work by attaching a cancer-killing payload directly to an antibody, allowing it to home in on tumour cells with greater precision than conventional therapies. Tubulis has developed proprietary conjugation technology that Gilead believes can deliver this approach more selectively and effectively than existing methods with potential applications across a broad range of tumour types beyond its lead programmes.

The company’s most advanced drug, TUB-040, targets a protein called NaPi2b and is currently in mid-stage clinical trials for platinum-resistant ovarian cancer and non-small cell lung cancer — two areas with considerable unmet patient need. A second asset, TUB-030, which targets a different tumour marker called 5T4, has also shown early promise across several solid cancer types.

O’Day noted that a two-year prior collaboration with Tubulis had given Gilead strong conviction in both the science and the team before committing to a full acquisition. Tubulis co-founder and CEO Dominik Schumacher said joining Gilead would provide the global infrastructure and scientific depth needed to bring the platform to patients at scale, adding that the existing partnership had already demonstrated the potential of their technology to the acquirer.

Once complete, Tubulis will continue operating as a dedicated ADC research unit within Gilead. We will retain its Munich site, which houses integrated discovery, manufacturing, and clinical capabilities, as a centre for next-generation ADC innovation within the wider organisation.

The Numbers

Gilead is set to pay $3.15 billion upfront, with a further $1.85 billion available in milestone-linked payments, bringing the potential total value of the deal to $5 billion. The transaction is expected to close during the second quarter of 2026, subject to regulatory clearances. Funding will come from a mix of existing cash reserves and new debt issuance.

---

---

Related Topics and Keywords

ADC, Biopharma, cancer research, drugdevelopment, gilead, LifeSciences, mergers and acquisitions, Oncology, pharma news, tubulis